CABANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cabaletta Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.48+0.07 (+4.96%)
Close on Oct 19, 2026
- Market cap
- $223.72M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
93.6%
159M of 170M shares
Institutional holders
140
55 new, 23 sold out
Net institutional buying
74M
In Q2 2026
Insider trades, 12 months
8 buys · 0 sales
Net bought $296.21K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9,613,912 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Bihua Chen | 9,400,000 | 9.28% | 13G (passive) amendment | Dec 31, 2025 |
| Phillip Gross | 9,002,580 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Alyeska Investment Group, L.P. | 8,904,367 | 9.90% | 13G (passive) | Jun 30, 2025 |
| Norges Bank | 8,775,653 | 5.38% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 8,295,783 | 5.08% | 13G (passive) | Jun 30, 2026 |
| Israel A. Englander | 5,130,763 | 5.30% | 13G (passive) | Feb 11, 2026 |
| Adage Capital Partners, L.P. | 3,864,475 | 9.47% | 13G (passive) amendment | Dec 31, 2023 |
| Jennison Associates LLC | 24,267,980 | 11.40% | 13G (passive) amendment | May 29, 2026 |
| Prudential Financial Inc | 24,267,980 | 11.40% | 13G (passive) amendment | May 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 18,869,907 | 11.60% | 13G (passive) amendment | Jun 30, 2026 |
| Bain Capital Life Sciences Opportunities III, LP | 17,241,445 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Robert Atchinson | 14,174,758 | 8.43% | 13G (passive) amendment | Jun 30, 2026 |
| Cormorant Asset Management, LP | 10,000,000 | 5.95% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CABA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jennison Associates LLC | 20,033,730 | 11.82% | $62.30M | +11,063,152 | 0.04% |
| T. Rowe Price Investment Management, Inc. | 18,869,907 | 11.13% | $58.69K | +7,789,902 | 0.04% |
| Bain Capital Life Sciences Investors, LLC | 17,241,445 | 10.17% | $53.62M | +7,564,320 | 3.19% |
| BlackRock, Inc. | 10,754,701 | 6.34% | $33.45M | +8,381,698 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 9,174,758 | 5.41% | $28.53M | +345,000 | 0.04% |
| State Street Corp | 7,839,305 | 4.62% | $24.38M | +7,369,327 | 0.00% |
| Vanguard Capital Management LLC | 7,227,018 | 4.26% | $22.48M | +3,198,027 | 0.00% |
| Cormorant Asset Management, LP | 5,000,000 | 2.95% | $15.55M | −500,000 | 0.80% |
| Price T Rowe Associates Inc /Md/ | 4,418,674 | 2.61% | $13.74K | +3,976,397 | 0.00% |
| Woodline Partners LP | 4,200,142 | 2.48% | $13.06M | +2,949,900 | 0.04% |
| Norges Bank | 4,112,401 | 2.43% | $12.79M | New | 0.00% |
| Opaleye Management Inc. | 3,863,800 | 2.28% | $12.02M | +2,483,800 | 1.09% |
| Citadel Advisors LLC | 3,522,112 | 2.08% | $10.95M | New | 0.00% |
| Geode Capital Management, LLC | 3,459,464 | 2.04% | $10.76M | +2,326,219 | 0.00% |
| Franklin Resources Inc | 2,413,937 | 1.42% | $7.51M | New | 0.00% |
| Goldman Sachs Group Inc | 2,211,825 | 1.30% | $6.88M | +1,428,605 | 0.00% |
| Millennium Management LLC | 2,068,491 | 1.22% | $6.43M | −3,834,790 | 0.00% |
| Cantor Fitzgerald, L. P. | 1,600,002 | 0.94% | $4.98M | +835,002 | 0.03% |
| Marshall Wace, Llp | 1,565,939 | 0.92% | $4.87M | −613,879 | 0.00% |
| Renaissance Technologies LLC | 1,535,300 | 0.91% | $4.77M | −501,363 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 140 | 159M | 93.6% | 55 / 50 | 20 / 23 | 84M | 10M |
| Q1 2026 | 108 | 85M | 49.9% | 27 / 31 | 28 / 13 | 18M | 9M |
| Q4 2025 | 95 | 80M | 47.3% | 30 / 33 | 19 / 8 | 19M | 9M |
| Q3 2025 | 75 | 70M | 41.4% | 10 / 24 | 31 / 21 | 13M | 16M |
| Q2 2025 | 86 | 73M | 42.9% | 26 / 23 | 28 / 32 | 46M | 10M |
| Q1 2025 | 92 | 36M | 21.4% | 16 / 29 | 32 / 30 | 6M | 8M |
| Q4 2024 | 108 | 38M | 22.7% | 25 / 40 | 25 / 37 | 7M | 17M |
| Q3 2024 | 120 | 48M | 28.5% | 20 / 45 | 36 / 41 | 13M | 12M |
| Q2 2024 | 142 | 52M | 30.7% | 19 / 54 | 49 / 35 | 14M | 15M |
| Q1 2024 | 159 | 53M | 31.3% | 46 / 47 | 46 / 15 | 14M | 10M |
| Q4 2023 | 128 | 49M | 28.9% | 42 / 41 | 31 / 10 | 16M | 8M |
| Q3 2023 | 97 | 41M | 24.1% | 26 / 47 | 10 / 12 | 7M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CABA | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Value Fund, Inc. | 7,865,614 | 4.64% | $24.46M | 0.23% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,256,225 | 3.10% | $16.35M | 0.15% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,215,188 | 3.08% | $16.22M | 0.00% | Jun 30, 2026 |
| PGIM Jennison Health Sciences Fund | 4,960,717 | 2.93% | $18.75M | 1.35% | May 29, 2026 |
| iShares Russell 2000 ETF | 2,926,762 | 1.73% | $9.10M | 0.01% | Jun 30, 2026 |
| PGIM Jennison Small Company Fund | 2,696,273 | 1.59% | $8.39M | 0.24% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,878,039 | 1.11% | $5.84M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,795,663 | 1.06% | $5.58M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1,387,457 | 0.82% | $4.31M | 0.05% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,369,957 | 0.81% | $4.26M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,229,372 | 0.73% | $3.29M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,007,313 | 0.59% | $3.13M | 0.03% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 876,846 | 0.52% | $2.35M | 0.20% | Jul 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 746,576 | 0.44% | $2.32M | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 662,486 | 0.39% | $2.50M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven Nichtberger | President & CEO, Director | 1,394,483 | 0.82% | Mar 2, 2026 |
| David J. Chang | Chief Medical Officer | 8,800 | 0.01% | Mar 2, 2026 |
| Arun Das | Chief Business Officer | – | – | Mar 2, 2026 |
| Michael Gerard | General Counsel | 6,600 | 0.00% | Mar 2, 2026 |
| Anup Marda | Chief Financial Officer | 50,000 | 0.03% | Mar 2, 2026 |
| Gwendolyn Binder | President, Science & Tech. | 31,312 | 0.02% | Mar 2, 2026 |
| Steve Gavel | Chief Commercial Officer | 22,170 | 0.01% | Jan 21, 2026 |
| Catherine Bollard | Director | 5,405 | 0.00% | Jun 10, 2026 |
| Scott C. Brun | Director | – | – | Jun 10, 2026 |
| Mark Simon | Director | 154,205 | 0.09% | Jun 10, 2026 |
| Shawn Tomasello | Director | 22,725 | 0.01% | Jun 10, 2026 |
| Richard C. Henriques Jr | Director | – | – | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gwendolyn Binder President, Science & Tech. | Jan 21, 2026 | Buy | +11,312 | $2.19 | $24.77K | 31,312 |
| Steve Gavel Chief Commercial Officer | Jan 21, 2026 | Buy | +22,170 | $2.27 | $50.33K | 22,170 |
| Steven Nichtberger President & CEO, Director | Jan 21, 2026 | Buy | +45,000 | $2.24 | $100.80K | 1,031,483 |
| Mark Simon Director | Jan 21, 2026 | Buy | +11,061 | $2.28 | $25.22K | 147,205 |
| Shawn Tomasello Director | Jan 21, 2026 | Buy | +22,725 | $2.21 | $50.22K | 22,725 |
| Michael Gerard General Counsel | Jan 21, 2026 | Buy | +6,600 | $2.27 | $14.98K | 6,600 |
| Catherine Bollard Director | Jan 21, 2026 | Buy | +4,405 | $2.27 | $10.00K | 5,405 |
| David J. Chang Chief Medical Officer | Jan 21, 2026 | Buy | +8,800 | $2.26 | $19.89K | 8,800 |
| Gwendolyn Binder See Remarks | Jan 19, 2024 | Sale(10b5-1 plan) | −700 | $20.33 | $14.23K | 20,000 |
| Gwendolyn Binder See Remarks | Jan 19, 2024 | Sale(10b5-1 plan) | −10,300 | $19.54 | $201.26K | 20,700 |
| Gwendolyn Binder See Remarks | Jan 19, 2024 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | Dec 19, 2023 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | Dec 19, 2023 | Sale(10b5-1 plan) | −7,868 | $21.76 | $171.21K | 23,132 |
| Gwendolyn Binder See Remarks | Dec 19, 2023 | Sale(10b5-1 plan) | −3,132 | $22.22 | $69.59K | 20,000 |
| Gwendolyn Binder See Remarks | Nov 20, 2023 | Sale(10b5-1 plan) | −7,458 | $18.02 | $134.39K | 20,000 |
| Gwendolyn Binder See Remarks | Nov 20, 2023 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | Nov 20, 2023 | Sale(10b5-1 plan) | −3,542 | $17.39 | $61.60K | 27,458 |
| Gwendolyn Binder See Remarks | Oct 19, 2023 | Sale(10b5-1 plan) | −408 | $14.28 | $5.83K | 20,000 |
| Gwendolyn Binder See Remarks | Oct 19, 2023 | Sale(10b5-1 plan) | −10,592 | $13.32 | $141.09K | 20,408 |
| Gwendolyn Binder See Remarks | Oct 19, 2023 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | Sep 19, 2023 | Sale(10b5-1 plan) | −10,300 | $17.50 | $180.25K | 20,700 |
| Gwendolyn Binder See Remarks | Sep 19, 2023 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | Sep 19, 2023 | Sale(10b5-1 plan) | −700 | $18.50 | $12.95K | 20,000 |
| Gwendolyn Binder See Remarks | Aug 21, 2023 | Sale(10b5-1 plan) | −300 | $13.82 | $4.15K | 20,000 |
| Gwendolyn Binder See Remarks | Aug 21, 2023 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | Aug 21, 2023 | Sale(10b5-1 plan) | −10,700 | $13.41 | $143.49K | 20,300 |
| Gwendolyn Binder See Remarks | Jul 19, 2023 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | Jul 19, 2023 | Sale(10b5-1 plan) | −8,185 | $13.67 | $111.89K | 22,815 |
| Gwendolyn Binder See Remarks | Jul 19, 2023 | Sale(10b5-1 plan) | −2,815 | $14.26 | $40.14K | 20,000 |
| Gwendolyn Binder See Remarks | Jun 20, 2023 | Sale(10b5-1 plan) | −11,000 | $12.99 | $142.89K | 20,000 |
| Gwendolyn Binder See Remarks | Jun 20, 2023 | Option exercise | +11,000 | $1.01 | $11.11K | 31,000 |
| Gwendolyn Binder See Remarks | May 19, 2023 | Sale(10b5-1 plan) | −22,000 | $11.81 | $259.82K | 20,000 |
| Gwendolyn Binder See Remarks | May 19, 2023 | Option exercise | +22,000 | $1.01 | $22.22K | 42,000 |
| Steven Nichtberger President & CEO, Director | Oct 19, 2022 | Buy | +8,127 | $1.25 | $10.16K | 986,483 |
| Anup Marda Chief Financial Officer | Oct 18, 2022 | Buy | +50,000 | $0.99 | $49.50K | 50,000 |
| Steven Nichtberger President & CEO, Director | Oct 18, 2022 | Buy | +141,873 | $0.99 | $140.45K | 978,356 |
| Mark Simon Director | Oct 18, 2022 | Buy | +7,000 | $0.98 | $6.86K | 7,000 |
| Mark Simon Director | Oct 18, 2022 | Buy | +118,000 | $0.98 | $115.64K | 136,144 |
| Catherine Bollard Director | Oct 18, 2022 | Buy | +1,000 | $0.99 | $990 | 1,000 |
| Gwendolyn Binder See Remarks | Oct 18, 2022 | Buy | +20,000 | $0.99 | $19.80K | 20,000 |
| Steven Nichtberger President & CEO, Director | Jan 31, 2022 | Option exercise | +50,000 | $1.01 | $50.50K | 836,483 |
| 5AM Partners V, LLC 10% owner | Nov 1, 2021 | Sale | −36,544 | $13.00 | $475.07K | 333,144 |
| 5AM Partners V, LLC 10% owner | Nov 1, 2021 | Sale | −258,456 | $13.00 | $3.36M | 1,731,119 |
| 5AM Ventures V, L.P. 10% owner | Sep 7, 2021 | Sale | −625,000 | $9.70 | $6.06M | 1,989,575 |
| Scott M. Rocklage 10% owner | Jan 12, 2021 | Sale | −74,470 | $13.00 | $968.11K | 2,614,575 |
| Scott M. Rocklage 10% owner | Jan 12, 2021 | Sale | −10,530 | $13.00 | $136.89K | 369,688 |
| Scott M. Rocklage 10% owner | Jan 8, 2021 | Sale | −37,411 | $13.00 | $486.34K | 380,218 |
| Scott M. Rocklage 10% owner | Jan 8, 2021 | Sale | −264,589 | $13.00 | $3.44M | 2,689,045 |
| Andrew J. Schwab 10% owner | Dec 10, 2020 | Sale | −36,916 | $14.75 | $544.51K | 417,629 |
| Andrew J. Schwab 10% owner | Dec 10, 2020 | Sale | −261,084 | $14.75 | $3.85M | 2,953,634 |
| Andrew J. Schwab 10% owner | Oct 29, 2019 | Buy | +454,545 | $11.00 | $5.00M | 454,545 |
| Andrew J. Schwab 10% owner | Oct 29, 2019 | Conversion | +3,214,721 | – | – | 3,214,721 |
| Deerfield Management Company, L.P. 10% owner | Oct 29, 2019 | Buy | +700,000 | $11.00 | $7.70M | 700,000 |
| Deerfield Management Company, L.P. 10% owner | Oct 29, 2019 | Conversion | +464,253 | – | – | 464,253 |
| Deerfield Management Company, L.P. 10% owner | Oct 29, 2019 | Conversion | +464,253 | – | – | 464,253 |
| Steven Nichtberger President & CEO, Director | Oct 29, 2019 | Conversion | +60,483 | – | – | 786,483 |
| Mark Simon Director | Oct 29, 2019 | Conversion | +18,144 | – | – | 18,144 |
| Jeremy Green 10% owner | Oct 29, 2019 | Conversion | +696,378 | – | – | 696,378 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Binder Gwendolyn Officer | Nov 20, 2023 | 33,000 | $592.68K | Nov 20, 2023 | Exercise of Stock Options |
| Binder Gwendolyn Officer | Oct 19, 2023 | 11,000 | $148.01K | Oct 19, 2023 | Exercise of Stock Options |
| Binder Gwendolyn Officer | Sep 19, 2023 | 11,000 | $205.15K | Sep 19, 2023 | Exercise of Stock Options |
| Binder Gwendolyn Officer | Aug 21, 2023 | 11,000 | $139.48K | Aug 21, 2023 | Exercise of Stock Options |
| Binder Gwendolyn Officer | Jul 19, 2023 | 11,000 | $153.78K | Jul 19, 2023 | Exercise of Stock Options |
| Binder Gwendolyn Officer | Jun 20, 2023 | 11,000 | $144.32K | Jun 20, 2023 | Exercise of Stock Options |
| Binder Gwendolyn Officer | Jun 20, 2023 | 11,000 | $144.32K | Jun 20, 2023 | Exercise of Stock Options |
| Binder Gwendolyn Officer | May 19, 2023 | 22,000 | $270.60K | May 19, 2023 | Exercise of Stock Options |